Your browser doesn't support javascript.
loading
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study.
Krishnan, Sreenath M; Friberg, Lena E; Mercier, François; Zhang, Rong; Wu, Ben; Jin, Jin Y; Hoang, Tien; Ballinger, Marcus; Bruno, René; Karlsson, Mats O.
Affiliation
  • Krishnan SM; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Friberg LE; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Mercier F; Biostatistics, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Zhang R; Clinical Pharmacology, Genentech, South San Francisco, California, USA.
  • Wu B; Clinical Pharmacology, Genentech, South San Francisco, California, USA.
  • Jin JY; Clinical Pharmacology, Genentech, South San Francisco, California, USA.
  • Hoang T; Product Development, Genentech, South San Francisco, California, USA.
  • Ballinger M; Product Development, Genentech, South San Francisco, California, USA.
  • Bruno R; Clinical Pharmacology, Roche/Genentech, Marseille, France.
  • Karlsson MO; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Clin Pharmacol Ther ; 113(4): 851-858, 2023 04.
Article in En | MEDLINE | ID: mdl-36606486
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Clin Pharmacol Ther Year: 2023 Type: Article Affiliation country: Sweden
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Clin Pharmacol Ther Year: 2023 Type: Article Affiliation country: Sweden